Faculty: Philip Seeman, MD, PhD

Philip Seeman, MD, PhDPhilip Seeman, MD, PhD
Professor Emeritus

General Research Area: Neuropharmacology
Transmitter Receptors and Genes in Brain in Health and Disease

Not taking new graduate students
 

Selected Publications:  (Peer-reviewed full-length publications in square brackets)

  1. 115.[78].      SEEMAN, P., CHAU-WONG, M., TEDESCO, J. and WONG, K.:  Brain receptors for antipsychotic drugs and dopamine:  Direct binding assays.  Proc. Nat. Acad. Sci., U.S.A. 72: 4376-4380 (1975).                                 
  2. 118.[79].      SEEMAN, P., LEE, T., CHAU-WONG, M. and WONG, K.: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261: 717-719 (1976).
  3. 307.[199].    SEEMAN, P., ULPIAN, C., BERGERON, C., RIEDERER, P., JELLINGER, K., GABRIEL, E., REYNOLDS, G.P. and TOURTELLOTTE, W.W.: Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 225: 728-731 (1984).
  4. 431.[284].    SUNAHARA, R.K., GUAN, H.-C., O’DOWD, B., SEEMAN, P., LAURIER, L.G., NG, G., GEORGE, S., TORCHIA, J., VAN TOL, H.H.M., and NIZNIK, H.B.: Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350: 614-619 (1991).
  5. 548.[355].    SEEMAN, P., and TALLERICO, T.: Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine. Amer. J. Psychiat. 156: 876-884 (1999).
  6. 565.[369].    KAPUR, S., and SEEMAN, P.: Does Fast Dissociation From the Dopamine D2 receptor Explain the Action of Atypical Antipsychotics? - A New Hypothesis. Am. J. Psychiat. 158: 360-369 (2001).
  7. 613.[405]     SEEMAN, P., WEINSHENKER, D., QUIRION, R., SRIVASTAVA, L., BHARDWAJ, S.K., GRANDY, D.K., PREMONT, R., SOTNIKOVA, T., BOKSA, P., EL-GHUNDI, M., O’DOWD B.F., GEORGE S.R.,  PERREAULT, M.L., MANNISTO, P.T., ROBINSON, S., PALMITER, R.D., and TALLERICO, T.: Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Nat. Acad. Sci. U.S.A. 102: 3513-3518 (2005).
  8. 717.[478].    SEEMAN, P. : All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neuroscience and therapeutics. 17(2): 118-132 (2011).
  9. 777.[502].    SEEMAN, P.: Schizophrenia thalamus imaging: Low benzamide binding to dopamine D2 receptors suggests fewer D2Short receptors and less presynaptic terminals. Psychiatry Research: Neuroimaging 214: 175-180 (2013).
  10. 790.[510].    SEEMAN, P.: Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69: 183-189 (2015).
  11. 792.[511].    DURDAGI, S., SALMAS, R.E., STEIN, M., YURTSEVER, M., SEEMAN, P.:  Binding interactions of dopamine and apomorphine in D2High and D2Low states of human dopamine D2 receptor (D2R) using computational and experimental techniques.                                          (American Chemical Society Chemical Neuroscience, 7(2) 185-195 (2016).
  12. 795.[514].    SEEMAN, P. Cannabidiol is a partial dopamine agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry 6, e920 (2016).

Contact:

Email: philip.seeman@utoronto.ca

Back to Top